View Alert
Versions:


Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 29-Jun-2021 12:07:42. This version was issued on 29-Jun-2021 12:07:42

This alert has been issued to:
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: COVID-19 Therapeutic Alert - Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants

Broadcast content: Palivizumab, administered as an intramuscular injection, is used to provide protection against respiratory syncytial virus (RSV) in at-risk patients, and has been shown to decrease hospitalisation in this group. 

It is currently part of a UK-wide immunisation schedule under guidance issued by Joint Committee on Vaccination and Immunisation (JCVI), which recommends its use in premature infants with conditions affecting the lungs and/or heart, and children with impaired immune systems. 

The UK rapid policy statement, which extends the eligibility criteria for passive immunisation with palivizumab (within the context of the current COVID-19 pandemic) to a further group of at-risk infants, has been updated to reflect the unusual seasonal presentation of the virus, and now allows for up to 7 doses to be administered. 

It is recommended that immunisation with palivizumab is initiated as soon as possible in line with the updated rapid policy statement. 


Alert reference: CEM/CMO/2021/014

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency